Stock Track | RemeGen Shares Surge Despite Q3 Loss on Strong Revenue Growth

Stock Track

Oct 30, 2024

Shares of biopharmaceutical company RemeGen Co., Ltd. (HKG:9995, SHA:688331) soared 17.59% on Tuesday, October 30, despite the company reporting a net loss for the third quarter of 2024. The surge came as investors focused on RemeGen's robust revenue growth during the period.

For the quarter ended September 30, RemeGen posted a net loss attributable to shareholders of 291.0 million yuan ($41.1 million). However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan ($66.0 million), indicating strong underlying business performance.

The positive revenue growth figures appeared to overshadow the net loss concerns, as investors bid up RemeGen's shares in both Hong Kong and Shanghai markets. The company's Hong Kong-listed shares gained 3% in morning trade on Wednesday, while its Shanghai-listed shares rose nearly 4%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130951207"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130951207\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130951207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130951207","market":"hk","top_or_hot":-1,"title":"Stock Track | RemeGen Shares Surge Despite Q3 Loss on Strong Revenue Growth","media":"Stock Track","content":"<p>Shares of biopharmaceutical company RemeGen Co., Ltd. (HKG:9995, SHA:688331) soared 17.59% on Tuesday, October 30, despite the company reporting a net loss for the third quarter of 2024. The surge came as investors focused on RemeGen's robust revenue growth during the period.</p>\n\n<p>For the quarter ended September 30, RemeGen posted a net loss attributable to shareholders of 291.0 million yuan ($41.1 million). However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan ($66.0 million), indicating strong underlying business performance.</p>\n\n<p>The positive revenue growth figures appeared to overshadow the net loss concerns, as investors bid up RemeGen's shares in both Hong Kong and Shanghai markets. The company's Hong Kong-listed shares gained 3% in morning trade on Wednesday, while its Shanghai-listed shares rose nearly 4%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | RemeGen Shares Surge Despite Q3 Loss on Strong Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | RemeGen Shares Surge Despite Q3 Loss on Strong Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of biopharmaceutical company RemeGen Co., Ltd. (HKG:9995, SHA:688331) soared 17.59% on Tuesday, October 30, despite the company reporting a net loss for the third quarter of 2024. The surge came as investors focused on RemeGen's robust revenue growth during the period.</p>\n\n<p>For the quarter ended September 30, RemeGen posted a net loss attributable to shareholders of 291.0 million yuan ($41.1 million). However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan ($66.0 million), indicating strong underlying business performance.</p>\n\n<p>The positive revenue growth figures appeared to overshadow the net loss concerns, as investors bid up RemeGen's shares in both Hong Kong and Shanghai markets. The company's Hong Kong-listed shares gained 3% in morning trade on Wednesday, while its Shanghai-listed shares rose nearly 4%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1130951207","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130951207","pubTimestamp":1730282661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of biopharmaceutical company RemeGen Co., Ltd.  soared 17.59% on Tuesday, October 30, despite the company reporting a net loss for the third quarter of 2024. The surge came as investors focused on RemeGen's robust revenue growth during the period.For the quarter ended September 30, RemeGen posted a net loss attributable to shareholders of 291.0 million yuan . However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan , indicating strong underlying busi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"尽管第三季度收入强劲增长导致亏损，但RemeGen股价仍飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"Shares of biopharmaceutical company RemeGen Co., Ltd. (HKG:9995, SHA:688331) soared 17.59% on Tuesday, October 30, despite the company reporting a net loss for the third quarter of 2024. The surge came as investors focused on RemeGen's robust revenue growth during the period.\nFor the quarter ended September 30, RemeGen posted a net loss attributable to shareholders of 291.0 million yuan ($41.1 million). However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan ($66.0 million), indicating strong underlying business performance.\nThe positive revenue growth figures appeared to overshadow the net loss concerns, as investors bid up RemeGen's shares in both Hong Kong and Shanghai markets. The company's Hong Kong-listed shares gained 3% in morning trade on Wednesday, while its Shanghai-listed shares rose nearly 4%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}